| Utestående aktier | 1,801,848 shares |
| Insideraktier | 5 468 325 shares |
| Totalt antal insynspersoner | 40 |
Insider Sentiment Score
Insider sentiment score hittar de företag som köps av foretagsinsynspersoner.
Det är resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av insiderackumulation. Poängmodellen använder en kombination av nettoantalet insiders som köpt de föregående 90 dagarna, det totala antalet aktier som köpts i procent av aktiekapitalet och det totala antalet aktier som ägs av insiders. Siffran sträcker sig från 0 till 100, med högre siffror som indikerar en högre nivå av ackumulering för sina kamrater, och 50 är genomsnittet.
Uppdateringsfrekvens: Dagligen
Se Insiders Top Picks, som ger en lista över företag med högsta insiderackumulation.
Office Sentiment Score
Officersentiment Score hittar företag som köps av Corporate Officers.
Per definition Corporate Officers är Corporate Insiders, men till skillnad från vissa av de andra Insiders (10 % aktieägare och styrelseledamöter), arbetar ämbetsmän för företaget dagligen och de använder sina egna pengar när de handlar . (10 % aktieägare och styrelseledamöter är ofta fondförvaltare som förvaltar andras pengar.) Som sådan är insideraffärer som görs av tjänstemän mycket mer betydelsefulla och bör behandlas på lämpligt sätt.
Liksom Insider Sentiment Score är Officer Sentiment Score resultatet av en sofistikerad, kvantitativ multifaktormodell som identifierar företag med de högsta nivåerna av officersackumulering.
Uppdateringsfrekvens: Dagligen
Se insiderns bästa val, vilket ger en lista över företag med högsta insider sentiment.
Viktiga insidernyckeltal
Denna kort visar hur företaget rankas längs olika insidernyckeltal. Procenttilrankningen visar hur detta företag jämförs med andra företag på USA-marknaden. Högre rankingar indikerar bättre situationer.
Till exempel anses det allmänt att insiderköp är en positiv indikator, så företag med mer insiderköp skulle rankas högre än företag med mindre insiderköp (eller til och med insiderförsäljning).
Procent av flytande köpta av insiders (ranking)
0.000 %( )
2664 out of 11219Procentandelen av aktier köpta av insiders är det totala antalet aktier som köpts av insiders minus det totala antalet aktier som sålts av insiders under de senaste 90 dagarna, dividerat med det totala antalet aktier och multiplicerat med 100.
Insiderhandelsdiagram
Telesis Bio, Inc. insideraffärer visas i följande diagram. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. I allmänhet är det i allmänhet olagligt för insiders att göra affärer i sina företag baserat på väsentlig, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4.
Insiderlista och lönsamhetsstatistik
Den här tabellen visar listan över kända insiders och genereras automatiskt från anmälningar som avslöjas till SEC. Förutom namnen, den senaste titeln och direktören, tjänstemannen eller ägarbeteckningen på 10 %, tillhandahåller vi de senaste avslöjade innehaven. Dessutom, när det är möjligt tillhandahåller vi insiderns historiska handelsresultat. Det historiska handelsresultatet är ett vägt genomsnitt av resultatet för faktiska köptransaktioner på den öppna marknaden som insidern gjort. För mer information om hur detta beräknas, titta på detta YouTube-webinarium.
See our leaderboard of most profitable insider traders.
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
|
Atlas Venture Associates VIII, Inc.
10% Owner -
|
3 922 010 | 217 889 | |
|
Atlas Venture Associates VIII, L.P.
10% Owner -
|
3 922 010 | 217 889 | |
|
Atlas Venture Fund VIII, L.P.
10% Owner -
|
3 922 010 | 217 889 | |
|
Baupost Group Llc/ma
10% Owner -
|
0 | 0 | |
| Ann Barbier | 150 000 | ||
|
Baupost Group GP, L.L.C.
10% Owner -
|
0 | 0 | |
| Daniella Beckman | 0 | ||
| Burgess Paul D. Chief Operating Officer, CLO - [O] | 0 | 0 | |
| Paula Cloghessy See Remarks - [O] | 102 480 | 5 693 | |
| George Demetri | 0 | ||
| Jean Francois Formela Director - [D] | 0 | 0 | |
| Brian Fenton Chief Business Officer - [O] | 250 990 | 13 944 | |
|
Plc Glaxosmithkline
10% Owner -
|
3 697 912 | 205 440 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
| Gallagher Brian M. Jr. Director - [D] | 3 697 912 | 205 440 | |
| Michael Heartlein See Remarks - [O] | 36 000 | 2 000 | |
| Owen Hughes Director - [D] | 0 | 0 | |
|
Seth A Klarman
10% Owner -
|
0 | 0 | |
| Daniel Lynch Director - [D] | 643 650 | 35 758 | |
|
Lim Richard J.
10% Owner -
|
1 458 424 | 81 024 | |
|
MRL Ventures Fund LLC
10% Owner -
|
1 873 503 | 104 084 | |
| Meyer Robert J. | 0 | ||
|
Claudio Nessi
10% Owner -
|
1 458 424 | 81 024 | |
|
Omega Fund IV G.P. Manager, Ltd.
10% Owner -
|
1 458 424 | 81 024 | |
|
Omega Fund IV GP, L.P.
10% Owner -
|
1 458 424 | 81 024 | |
|
Omega Fund IV, L.P.
10% Owner -
|
1 458 424 | 81 024 | |
|
Omega Fund V GP Manager, Ltd.
10% Owner -
|
1 458 424 | 81 024 |
| Insider | Genomsnitt vinst (%) | Aktier Ägda |
Delad Justerad |
|---|---|---|---|
|
Omega Fund V GP, L.P.
10% Owner -
|
1 458 424 | 81 024 | |
|
Omega Fund V, L.P.
10% Owner -
|
1 458 424 | 81 024 | |
|
Anne-Mari Paster
10% Owner -
|
1 458 424 | 81 024 | |
| Robert M Plenge | 0 | ||
| Ronald C JR Renaud Chief Executive Officer, Director - [D] [O] | 0 | 0 | |
|
Sanofi
10% Owner -
|
75 668 031 | 4 203 780 | |
| Schroer John R. | 150 000 | ||
|
Shire Human Genetic Therapies, Inc.
10% Owner -
|
0 | 0 | |
|
plc Shire
10% Owner -
|
7 078 945 | 393 275 | |
| Brendan Smith | 0 | ||
|
Otello Stampacchia
10% Owner -
|
1 458 424 | 81 024 | |
| Everett Rand Sutherland | 0 | ||
|
Pharmaceutical Co Ltd Takeda
10% Owner -
|
0 | 0 | |
| Richard Wooster | 150 000 |
Report errors via our new Insider Auditing Tool
Track Records av insiderköp - Kortsiktig vinstanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i TBIO / Telesis Bio, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste köpen på öppna marknaden som inte var en del av en automatisk handelsplan.
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Track Records av insiderförsäljning - Kortsiktig förlustanalys
I denna sektion analyserar vi lönsamheten för varje oplanerat, öppet-marknads insiderköp gjorda i TBIO / Telesis Bio, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormala avkastningar och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste försäljningarna på öppna marknaden som inte var en del av en automatisk handelsplan.
| Handelsdatum | Insider | Rapporterade aktier |
Rapporterat pris |
Justerade aktier |
Justerat pris |
Kostnadsbasis | Dagar til Min |
Pris vid Min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
|---|---|---|---|---|---|---|---|
| Det finns inga kända oplanerade öppna marknadstransaktioner för denna insynsperson |
Justeringar av aktierär de justerade aktierna efter justerat pris. Justeringar av aktierär de justerade aktierna efter uppdelning.
Transaktionshistorik
Klicka på länkikonen för att se hela transaktionshistoriken. Transaktioner som rapporteras som en del av en automatisk handelsplan 10b5-1 kommer att ha ett X i kolumnen markerad 10b-5.
| Fil datum |
Handel datum |
Schema | Insider | Ticker | Värdepappertitel | Kod | Direkta | Utövningspris | Enhet pris |
Enheter ändrad |
Värde ändrad (1K) |
Kvarvarande Optioner |
Kvarvarande Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-16 | 2021-09-14 | 4/A | BAUPOST GROUP LLC/MA See footnote 1 and 2 | TBIO | Common Stock | I | 38,0000 | −18 044 239 | −685 681 | 0 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Sutherland Everett Rand | TBIO | Stock Option (right to buy) | D | 16,37 | −300 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Smith Brendan | TBIO | Stcok Option (right to buy) | D | 19,23 | −201 800 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 8,34 | −89 996 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,39 | −1 071 009 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR | TBIO | Stcok Option (right to buy) | D | 23,82 | −325 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,66 | −525 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,95 | −500 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR By Ronald C. Renaud, Jr. Trust - 2007 | TBIO | Common Stock | I | 38,0000 | −40 909 | −1 555 | 0 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR By Ronald Renaud 2014 Irrevocable Family Trust | TBIO | Common Stock | I | 38,0000 | −409 913 | −15 577 | 0 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Renaud Ronald C JR | TBIO | Common Stock | D | 38,0000 | −503 231 | −19 123 | 0 | ||||
| 2021-09-14 | 2021-04-07 | 4/A | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,39 | −9 026 | 1 071 009 | |||||
| 2021-09-14 | 2021-04-07 | 4/A | Renaud Ronald C JR | TBIO | Common Stock | D | 7,3900 | 9 026 | 67 | 503 231 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 23,82 | −90 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 7,95 | −150 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 7,66 | −150 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 8,34 | −69 953 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 7,39 | −219 652 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Burgess Paul D. | TBIO | Common Stock | D | 38,0000 | −71 833 | −2 730 | 0 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 20,43 | −20 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 15,33 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 10,20 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 12,36 | −37 800 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 20,43 | −20 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 10,20 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 15,33 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 7,49 | −37 800 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Hughes Owen | TBIO | Stock Option (righ to buy) | D | 20,43 | −20 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Hughes Owen | TBIO | Stock Option (right to buy) | D | 15,33 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Hughes Owen | TBIO | Stock Option (right to buy) | D | 10,20 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Hughes Owen | TBIO | Stock Option (right to buy) | D | 7,39 | −38 135 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Hughes Owen | TBIO | Common Stock | D | 38,0000 | −29 860 | −1 135 | 0 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 20,43 | −20 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 15,33 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 10,15 | −37 800 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | FORMELA JEAN FRANCOIS | TBIO | Stock Option (right to buy) | D | 8,34 | −37 800 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | FORMELA JEAN FRANCOIS | TBIO | Stock Option (right to buy) | D | 20,43 | −20 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | FORMELA JEAN FRANCOIS | TBIO | Stock Option (right to buy) | D | 15,33 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | FORMELA JEAN FRANCOIS | TBIO | Stock Option (right to buy) | D | 10,20 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock | I | 38,0000 | −2 055 063 | −78 092 | 0 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 20,43 | −20 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 15,33 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 10,15 | −37 800 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Beckman Daniella | TBIO | Stock Option (right to buy) | D | 20,43 | −20 000 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Beckman Daniella | TBIO | Stock Option (right to buy) | D | 15,33 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Beckman Daniella | TBIO | Stock Option (right to buy) | D | 10,20 | −18 900 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Beckman Daniella | TBIO | Stock Option (right to buy) | D | 7,39 | −67 995 | 0 | |||||
| 2021-09-14 | 2021-09-14 | 4 | Sanofi | TBIO | Common Stock, par value $0.001 per share | D | 38,0000 | 20 515 985 | 779 607 | 75 668 031 | ||||
| 2021-09-14 | 2021-09-14 | 4 | Sanofi | TBIO | Common Stock, par value $0.001 per share | D | 38,0000 | 51 467 612 | 1 955 769 | 55 152 046 | ||||
| 2021-08-12 | 3 | Sanofi | TBIO | Common Stock | D | 3 684 434 | ||||||||
| 2021-06-17 | 2021-06-16 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock (right to buy) | D | 20,43 | 20 000 | 20 000 | |||||
| 2021-06-16 | 2021-06-16 | 4 | Beckman Daniella | TBIO | Stock Option (right to buy) | D | 20,43 | 20 000 | 20 000 | |||||
| 2021-06-16 | 2021-06-16 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 20,43 | 20 000 | 20 000 | |||||
| 2021-06-16 | 2021-06-16 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 20,43 | 20 000 | 20 000 | |||||
| 2021-06-16 | 2021-06-16 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 20,43 | 20 000 | 20 000 | |||||
| 2021-06-16 | 2021-06-16 | 4 | Hughes Owen | TBIO | Stock Option (right to buy) | D | 20,43 | 20 000 | 20 000 | |||||
| 2021-04-20 | 2021-04-19 | 4 | Smith Brendan | TBIO | Stock Option (Right to Buy) | D | 19,23 | 201 800 | 201 800 | |||||
| 2021-04-09 | 2021-04-07 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,39 | −9 026 | 1 071 009 | |||||
| 2021-04-09 | 2021-04-07 | 4 | Renaud Ronald C JR | TBIO | Common Stock | D | 7,3900 | 9 026 | 67 | 503 321 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Sutherland Everett Rand | TBIO | Stock Option (right to buy) | D | 16,37 | 300 000 | 300 000 | |||||
| 2021-03-09 | 2021-03-09 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 23,82 | 325 000 | 325 000 | |||||
| 2021-03-09 | 2021-03-09 | 4 | Wooster Richard | TBIO | Stock Option (right to buy) | D | 23,82 | 70 000 | 70 000 | |||||
| 2021-03-09 | 2021-03-09 | 4 | Barbier Ann | TBIO | Stock Option (right to buy) | D | 23,82 | 70 000 | 70 000 | |||||
| 2021-03-09 | 2021-03-09 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 23,82 | 90 000 | 90 000 | |||||
| 2021-01-14 | 2021-01-14 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 8,34 | −1 | 89 996 | |||||
| 2021-01-14 | 2021-01-14 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,39 | −5 638 | 1 080 035 | |||||
| 2021-01-14 | 2021-01-14 | 4 | Renaud Ronald C JR | TBIO | Common Stock | D | 8,3400 | 1 | 0 | 494 205 | ||||
| 2021-01-14 | 2021-01-14 | 4 | Renaud Ronald C JR | TBIO | Common Stock | D | 7,3900 | 5 638 | 42 | 494 204 | ||||
| 2020-12-23 | 2020-12-22 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock | I | 25,8825 | −2 700 | −70 | 43 940 | ||||
| 2020-12-23 | 2020-12-22 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock | I | 25,0421 | −79 865 | −2 000 | 46 640 | ||||
| 2020-12-23 | 2020-12-21 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock | I | 25,5046 | −56 536 | −1 442 | 126 505 | ||||
| 2020-11-18 | 2020-11-16 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 8,34 | −3 | 89 997 | |||||
| 2020-11-18 | 2020-11-16 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,39 | −53 004 | 1 085 673 | |||||
| 2020-11-18 | 2020-11-16 | 4 | Renaud Ronald C JR | TBIO | Common Stock | D | 8,3400 | 3 | 0 | 488 566 | ||||
| 2020-11-18 | 2020-11-16 | 4 | Renaud Ronald C JR | TBIO | Common Stock | D | 7,3900 | 53 004 | 392 | 488 563 | ||||
| 2020-08-27 | 2020-08-27 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock | I | 14,3822 | −10 097 | −145 | 3 833 122 | ||||
| 2020-08-27 | 2020-08-26 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock | I | 14,7979 | −44 381 | −657 | 3 843 219 | ||||
| 2020-08-27 | 2020-08-25 | 4 | FORMELA JEAN FRANCOIS | TBIO | Common Stock | I | 15,0003 | −34 410 | −516 | 3 887 600 | ||||
| 2020-06-30 | 2020-06-30 | 4 | Shire Human Genetic Therapies, Inc. | TBIO | Common Stock | D | 20,6800 | −6 824 992 | −141 141 | 0 | ||||
| 2020-06-30 | 2020-06-26 | 4 | BAUPOST GROUP LLC/MA See footnote 1 and 2. | TBIO | Common Stock | I | 22,0000 | 500 000 | 11 000 | 18 044 239 | ||||
| 2020-06-17 | 2020-06-16 | 4 | Beckman Daniella | TBIO | Stock Option (right to buy) | D | 15,33 | 18 900 | 18 900 | |||||
| 2020-06-17 | 2020-06-16 | 4 | LYNCH DANIEL | TBIO | Stock Option (right to buy) | D | 15,33 | 18 900 | 18 900 | |||||
| 2020-06-17 | 2020-06-16 | 4 | FORMELA JEAN FRANCOIS | TBIO | Stock Option (right to buy) | D | 15,33 | 18 900 | 18 900 | |||||
| 2020-06-16 | 2020-06-16 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 15,33 | 18 900 | 18 900 | |||||
| 2020-06-16 | 2020-06-16 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 15,33 | 18 900 | 18 900 | |||||
| 2020-06-16 | 2020-06-16 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 15,33 | 18 900 | 18 900 | |||||
| 2020-06-16 | 2020-06-16 | 4 | Hughes Owen | TBIO | Stock Option (right to buy) | D | 15,33 | 18 900 | 18 900 | |||||
| 2020-06-05 | 2020-06-03 | 4 | Shire Human Genetic Therapies, Inc. | TBIO | Common Stock | D | 19,7500 | −40 086 | −792 | 6 824 992 | ||||
| 2020-06-03 | 3 | TAKEDA PHARMACEUTICAL CO LTD See Explanation of Responses | TBIO | Common Stock A | I | 14 157 890 | ||||||||
| 2020-06-03 | 3 | TAKEDA PHARMACEUTICAL CO LTD See Explanation of Responses | TBIO | Common Stock A | I | 14 157 890 | ||||||||
| 2020-06-03 | 3 | TAKEDA PHARMACEUTICAL CO LTD See Explanation of Responses | TBIO | Common Stock A | I | 14 157 890 | ||||||||
| 2020-06-03 | 2020-06-02 | 4 | Shire Human Genetic Therapies, Inc. | TBIO | Common Stock | D | 20,0200 | −5 006 | −100 | 6 865 078 | ||||
| 2020-06-03 | 2020-06-02 | 4 | Shire Human Genetic Therapies, Inc. | TBIO | Common Stock | D | 19,7500 | −100 389 | −1 983 | 6 870 084 | ||||
| 2020-06-03 | 2020-06-01 | 4 | Shire Human Genetic Therapies, Inc. | TBIO | Common Stock | D | 20,5300 | −1 400 | −29 | 6 970 473 | ||||
| 2020-06-03 | 2020-06-01 | 4 | Shire Human Genetic Therapies, Inc. | TBIO | Common Stock | D | 19,8500 | −107 072 | −2 125 | 6 971 873 | ||||
| 2020-03-05 | 2020-03-03 | 4 | Wooster Richard | TBIO | Stock Option (right to buy) | D | 7,66 | 150 000 | 150 000 | |||||
| 2020-03-05 | 2020-03-03 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,66 | 525 000 | 525 000 | |||||
| 2020-03-05 | 2020-03-03 | 4 | Schroer John R. | TBIO | Stock Option (right to buy) | D | 7,66 | 150 000 | 150 000 | |||||
| 2020-03-05 | 2020-03-03 | 4 | Barbier Ann | TBIO | Stock Option (right to buy) | D | 7,66 | 150 000 | 150 000 | |||||
| 2020-03-05 | 2020-03-03 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 7,66 | 150 000 | 150 000 | |||||
| 2019-09-20 | 3 | KLARMAN SETH A See footnote 1,2 | TBIO | Common Stock | I | 35 088 478 | ||||||||
| 2019-09-20 | 3 | KLARMAN SETH A See footnote 1,2 | TBIO | Common Stock | I | 35 088 478 | ||||||||
| 2019-09-20 | 3 | KLARMAN SETH A See footnote 1,2 | TBIO | Common Stock | I | 35 088 478 | ||||||||
| 2019-09-20 | 3 | KLARMAN SETH A See footnote 1,2 | TBIO | Common Stock | I | 35 088 478 | ||||||||
| 2019-09-20 | 3 | KLARMAN SETH A See footnote 1,2 | TBIO | Common Stock | I | 35 088 478 | ||||||||
| 2019-07-15 | 2019-07-12 | 4 | Demetri George | TBIO | Stock Option (right to buy) | D | 10,15 | 37 800 | 37 800 | |||||
| 2019-06-19 | 2019-06-18 | 4 | FORMELA JEAN FRANCOIS | TBIO | Stock Option (right to buy) | D | 10,20 | 18 900 | 18 900 | |||||
| 2019-06-19 | 2019-06-18 | 4 | Hughes Owen | TBIO | Stock Option (right to buy) | D | 10,20 | 18 900 | 18 900 | |||||
| 2019-06-19 | 2019-06-18 | 4 | LYNCH DANIEL | TBIO | Stock Option (right to buy) | D | 10,20 | 18 900 | 18 900 | |||||
| 2019-06-19 | 2019-06-18 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 10,20 | 18 900 | 18 900 | |||||
| 2019-06-19 | 2019-06-18 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 10,20 | 18 900 | 18 900 | |||||
| 2019-06-19 | 2019-06-18 | 4 | Beckman Daniella | TBIO | Stock Option (right to buy) | D | 10,20 | 18 900 | 18 900 | |||||
| 2019-04-26 | 2019-04-24 | 4 | Wooster Richard | TBIO | Stock Option (right to buy) | D | 9,40 | 360 000 | 360 000 | |||||
| 2019-04-11 | 2019-04-10 | 4 | Plenge Robert M | TBIO | Stock Option (right to buy) | D | 12,36 | 37 800 | 37 800 | |||||
| 2019-03-12 | 2019-03-08 | 4 | Schroer John R. | TBIO | Stock Option (right to buy) | D | 7,95 | 125 000 | 125 000 | |||||
| 2019-03-12 | 2019-03-08 | 4 | Barbier Ann | TBIO | Stock Option (right to buy) | D | 7,95 | 125 000 | 125 000 | |||||
| 2019-03-12 | 2019-03-08 | 4 | Burgess Paul D. | TBIO | Stock Option (right to buy) | D | 7,95 | 150 000 | 150 000 | |||||
| 2019-03-12 | 2019-03-08 | 4 | Cloghessy Paula | TBIO | Stock Option (right ot buy) | D | 7,95 | 60 000 | 60 000 | |||||
| 2019-03-12 | 2019-03-08 | 4 | Fenton Brian | TBIO | Stock Option (irght to buy) | D | 7,95 | 90 000 | 90 000 | |||||
| 2019-03-12 | 2019-03-08 | 4 | Heartlein Michael | TBIO | Stock Option (right to buy) | D | 7,95 | 150 000 | 150 000 | |||||
| 2019-03-12 | 2019-03-08 | 4 | Renaud Ronald C JR | TBIO | Stock Option (right to buy) | D | 7,95 | 500 000 | 500 000 | |||||
| 2019-01-03 | 2019-01-02 | 4 | Meyer Robert J. | TBIO | Stock Option (right to buy) | D | 7,49 | 37 800 | 37 800 | |||||
| 2018-07-05 | 2018-07-02 | 4 | Gallagher Brian M. Jr. | TBIO | Series C Preferred Stock | I | −2 525 253 | 0 | ||||||
| 2018-07-05 | 2018-07-02 | 4 | Gallagher Brian M. Jr. | TBIO | Series B Preferred Stock | I | −7 222 797 | 0 | ||||||
| 2018-07-05 | 2018-07-02 | 4 | Gallagher Brian M. Jr. | TBIO | Series A Preferred Stock | I | −9 300 000 | 0 | ||||||
| 2018-07-05 | 2018-07-02 | 4 | Gallagher Brian M. Jr. | TBIO | Common Stock | I | 13,0000 | 269 230 | 3 500 | 3 697 912 | ||||
| 2018-07-05 | 2018-07-02 | 4 | Gallagher Brian M. Jr. | TBIO | Common Stock | I | 454 550 | 3 428 682 | ||||||
| 2018-07-05 | 2018-07-02 | 4 | Gallagher Brian M. Jr. | TBIO | Common Stock | I | 1 300 116 | 2 974 132 | ||||||
| 2018-07-05 | 2018-07-02 | 4 | Gallagher Brian M. Jr. | TBIO | Common Stock | I | 1 674 016 | 1 674 016 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Renaud Ronald C JR By Ronald Renaud 2014 Irrevocable Family Trust | TBIO | Series C Preferred Stock | I | −227 272 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Renaud Ronald C JR By Ronald C. Renaud, Jr. Trust - 2007 | TBIO | Series C Preferred Stock | I | −227 272 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Renaud Ronald C JR By Ronald Renaud 2014 Irrevocable Family Trust | TBIO | Common Stock | I | 40 909 | 40 909 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Renaud Ronald C JR By Ronald C. Renaud, Jr. Trust - 2007 | TBIO | Common Stock | I | 40 909 | 40 909 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Atlas Venture Fund VIII, L.P. | TBIO | Series C Preferred Stock | D | −2 525 253 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Atlas Venture Fund VIII, L.P. | TBIO | Series B Preferred Stock | D | −5 838 230 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Atlas Venture Fund VIII, L.P. | TBIO | Series A Preferred Stock | D | −12 925 244 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Atlas Venture Fund VIII, L.P. | TBIO | Common Stock | D | 3 832 010 | 3 922 010 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Series C Preferred Stock | D | −302 173 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega V | TBIO | Series C Preferred Stock | I | −302 173 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Series B Preferred Stock | D | −2 000 103 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega V | TBIO | Series B Preferred Stock | I | −2 000 103 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Series A Preferred Stock | D | −5 800 000 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega V | TBIO | Series A Preferred Stock | I | −5 800 000 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega IV | TBIO | Series C Preferred Stock | I | −1 263 484 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Series C Preferred Stock | D | −1 263 484 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega IV | TBIO | Series B Preferred Stock | I | −1 676 348 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Series B Preferred Stock | D | −1 676 348 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Series A Preferred Stock | D | −2 500 000 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega IV | TBIO | Series A Preferred Stock | I | −2 500 000 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega V | TBIO | Common Stock | I | 1 458 424 | 1 458 424 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Common Stock | D | 1 458 424 | 1 458 424 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. | TBIO | Common Stock | D | 979 179 | 979 179 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | Omega Fund IV, L.P. By Omega IV | TBIO | Common Stock | I | 979 179 | 979 179 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | MRL Ventures Fund LLC | TBIO | Series C Preferred Stock | D | −1 010 101 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | MRL Ventures Fund LLC | TBIO | Series B Preferred Stock | D | −9 259 259 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | MRL Ventures Fund LLC | TBIO | Common Stock | D | 13,0000 | 25 000 | 325 | 1 873 503 | ||||
| 2018-07-03 | 2018-07-02 | 4 | MRL Ventures Fund LLC | TBIO | Common Stock | D | 1 848 503 | 1 848 503 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | FORMELA JEAN FRANCOIS By Atlas Venture Fund VIII, L.P. | TBIO | Series C Preferred Stock | I | −2 525 253 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | FORMELA JEAN FRANCOIS By Atlas Venture Fund VIII, L.P. | TBIO | Series B Preferred Stock | I | −5 838 230 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | FORMELA JEAN FRANCOIS By Atlas Venture Fund VIII, L.P. | TBIO | Series A Preferred Stock | I | −12 925 244 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | FORMELA JEAN FRANCOIS By Atlas Venture Fund VIII, L.P. | TBIO | Common Stock | I | 3 832 010 | 3 922 010 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | GLAXOSMITHKLINE PLC | TBIO | Series C Preferred Stock | I | −2 525 253 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | GLAXOSMITHKLINE PLC | TBIO | Series B Preferred Stock | I | −7 222 797 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | GLAXOSMITHKLINE PLC | TBIO | Series A Preferred Stock | I | −9 300 000 | 0 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | GLAXOSMITHKLINE PLC | TBIO | Common Stock | I | 13,0000 | 269 230 | 3 500 | 3 697 912 | ||||
| 2018-07-03 | 2018-07-02 | 4 | GLAXOSMITHKLINE PLC | TBIO | Common Stock | I | 454 550 | 3 428 682 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | GLAXOSMITHKLINE PLC | TBIO | Common Stock | I | 1 300 116 | 2 974 132 | ||||||
| 2018-07-03 | 2018-07-02 | 4 | GLAXOSMITHKLINE PLC | TBIO | Common Stock | I | 1 674 016 | 1 674 016 | ||||||
| 2018-07-02 | 2018-07-02 | 4 | Shire Human Genetic Therapies, Inc. | TBIO | Common Stock | D | 183 619 | 7 078 945 | ||||||
| 2018-06-27 | 3 | Shire plc | TBIO | Common Stock | D | 13 790 650 | ||||||||
| 2018-06-27 | 3 | Shire plc | TBIO | Common Stock | D | 13 790 650 | ||||||||
| 2018-06-27 | 3 | Shire plc | TBIO | Common Stock | D | 13 790 650 | ||||||||
| 2018-06-27 | 3 | Shire plc | TBIO | Common Stock | D | 13 790 650 | ||||||||
| 2018-06-27 | 3 | Burgess Paul D. | TBIO | Common Stock | D | 143 666 | ||||||||
| 2018-06-27 | 3 | Burgess Paul D. | TBIO | Common Stock | D | 143 666 | ||||||||
| 2018-06-27 | 3 | Burgess Paul D. | TBIO | Common Stock | D | 143 666 | ||||||||
| 2018-06-27 | 3 | Heartlein Michael | TBIO | Common Stock | D | 36 000 | ||||||||
| 2018-06-27 | 3 | Heartlein Michael | TBIO | Common Stock | D | 36 000 | ||||||||
| 2018-06-27 | 3 | Heartlein Michael | TBIO | Common Stock | D | 36 000 | ||||||||
| 2018-06-27 | 3 | LYNCH DANIEL | TBIO | Common Stock | D | 643 650 | ||||||||
| 2018-06-27 | 3 | LYNCH DANIEL | TBIO | Common Stock | D | 643 650 | ||||||||
| 2018-06-27 | 3 | LYNCH DANIEL | TBIO | Common Stock | D | 643 650 | ||||||||
| 2018-06-27 | 3 | Hughes Owen | TBIO | Common Stock | D | 59 720 | ||||||||
| 2018-06-27 | 3 | Hughes Owen | TBIO | Common Stock | D | 59 720 | ||||||||
| 2018-06-27 | 3 | Hughes Owen | TBIO | Common Stock | D | 59 720 | ||||||||
| 2018-06-27 | 3 | Renaud Ronald C JR By Ronald Renaud 2014 Irrevocable Family Trust | TBIO | Common Stock | I | 1 173 565 | ||||||||
| 2018-06-27 | 3 | Renaud Ronald C JR | TBIO | Common Stock | D | 1 240 121 | ||||||||
| 2018-06-27 | 3 | Renaud Ronald C JR By Ronald Renaud 2014 Irrevocable Family Trust | TBIO | Common Stock | I | 1 173 565 | ||||||||
| 2018-06-27 | 3 | Renaud Ronald C JR | TBIO | Common Stock | D | 1 240 121 | ||||||||
| 2018-06-27 | 3 | Renaud Ronald C JR By Ronald Renaud 2014 Irrevocable Family Trust | TBIO | Common Stock | I | 1 173 565 | ||||||||
| 2018-06-27 | 3 | Renaud Ronald C JR | TBIO | Common Stock | D | 1 240 121 | ||||||||
| 2018-06-27 | 3 | Fenton Brian | TBIO | Common Stock | D | 250 990 | ||||||||
| 2018-06-27 | 3 | Fenton Brian | TBIO | Common Stock | D | 250 990 | ||||||||
| 2018-06-27 | 3 | Fenton Brian | TBIO | Common Stock | D | 250 990 | ||||||||
| 2018-06-27 | 3 | Atlas Venture Associates VIII, Inc. | TBIO | Common Stock | D | 180 000 | ||||||||
| 2018-06-27 | 3 | Atlas Venture Associates VIII, Inc. | TBIO | Common Stock | D | 180 000 | ||||||||
| 2018-06-27 | 3 | Atlas Venture Associates VIII, Inc. | TBIO | Common Stock | D | 180 000 | ||||||||
| 2018-06-27 | 3 | Atlas Venture Associates VIII, Inc. | TBIO | Common Stock | D | 180 000 | ||||||||
| 2018-06-27 | 3 | Atlas Venture Associates VIII, Inc. | TBIO | Common Stock | D | 180 000 | ||||||||
| 2018-06-27 | 3 | Cloghessy Paula | TBIO | Common Stock | D | 102 480 | ||||||||
| 2018-06-27 | 3 | Cloghessy Paula | TBIO | Common Stock | D | 102 480 | ||||||||
| 2018-06-27 | 3 | Cloghessy Paula | TBIO | Common Stock | D | 102 480 | ||||||||
| 2018-06-27 | 3 | FORMELA JEAN FRANCOIS By Atlas Venture Fund VIII, L.P. | TBIO | Common Stock | I | 180 000 | ||||||||
| 2018-06-27 | 3 | FORMELA JEAN FRANCOIS By Atlas Venture Fund VIII, L.P. | TBIO | Common Stock | I | 180 000 | ||||||||
| 2018-06-27 | 3 | FORMELA JEAN FRANCOIS By Atlas Venture Fund VIII, L.P. | TBIO | Common Stock | I | 180 000 |
P
Köp på öppna marknaden eller privat köp av icke-derivatsäkerhet
S
Köp på öppna marknaden eller privat försäljning av icke-derivatsäkerhet
A
Bevilja, tilldelning eller annat förvärv av värdepapper från företaget (såsom en option)
C
Omvandling av derivat
D
Försäljning eller överföring av värdepapper tillbaka til företaget
F
Betalning av lösenpris eller skatteskuld med del av värdepapper som erhållits från bolaget
G
Överlåtelse av värdepapper från eller till insidern
K
Aktieswappar och liknande säkringsaffärer
M
Utövande eller omvandling av derivatsäkerhet som erhållits från företaget (som en option)
V
En transaktion friviligt rapporterad på schema 4
J
Andra (med en fotnot som beskriver transaktionen)
